Tech Company Financing Transactions
Arriva Pharmaceuticals Funding Round
Arriva Pharmaceuticals closed a $6 million funding round on 2/29/2008. Investors included MPM Capital and Nordic Biotech Advisors.
Transaction Overview
Company Name
Announced On
2/29/2008
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
6114 LaSalle Ave. 643
Oakland, CA 94611
USA
Oakland, CA 94611
USA
Phone
Website
Email Address
Overview
Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sue Preston
Browse more venture capital transactions:
Prev: 2/29/2008: NextIO venture capital transaction
Next: 2/29/2008: Naverus venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs